HOW IT WORKS
One trial. One orchestrator. One platform.
AllianceXPartners (AXP) sits at the center of every program as the contracting, financing, and licensing hub. AXP does not simply introduce the parties — it structures, coordinates, and manages the transaction from asset selection through value creation.
Linked agreements, one program
For each program, AXP brings together the biotech company, clinical and regulatory partners, trial sites, capital providers, and regional commercialization partners under a single coordinated structure. AXP negotiates the rights, organizes and funds the confirmatory clinical pathway, oversees execution, and holds the resulting royalty, warrant/equity participation, and selected geographic rights.
1. EAEU Licence & Development Agreement
Between the US biotech and AXP, sublicensed to the EAEU partner. Defines the regional rights being granted.
2. Trial Funding Agreement
EAEU partner funds AXP, which funds regional clinical trial. Cash flows in one direction, toward the trial.
3. Royalty, Warrant & Data Agreement
Between AXP and the US biotech. AXP receives a royalty and a warrant in exchange for delivering the FDA-usable data package — at no cash cost to the biotech.
Why the data package justifies the asking
A post-failure biotech faces a binary future. Without a funded confirmatory trial, the asset drifts toward wind-down. With FDA-usable sub-population data, it can be approved, partnered, or acquired — a step-change in value. AllianceXPartners supplies exactly the missing piece, without asking for cash the company doesn’t have. The royalty and warrant are priced against the value created, not the cash spent, because the EAEU partner funds the trial itself.
Completed project outlook
The objective is straightforward: move a stranded asset through its next major clinical and regulatory inflection point, unlock markets and licensing opportunities, increase the value of the underlying biotech company, and position the asset for partnership or acquisition by Big Pharma.
One asset → one coordinated trial → one value-inflection point → multiple paths to monetization.
AllianceXPartners 